On March 1, 2018, the Board of Directors of Spring Bank Pharmaceuticals, Inc. elected Timothy Clackson, Ph.D. to the Board as a class I director (independent) with a term expiring at the 2019 annual meeting of stockholders. Dr. Clackson most recently served as president of research and development at ARIAD Pharmaceuticals, Inc. until its acquisition by Takeda. He led the R&D team that discovered and brought to market two innovative targeted therapies for cancer, and moved three additional medicines into clinical development. Prior to his seven years as president of R&D, Dr. Clackson served as ARIAD’s senior vice president and chief scientific officer. Dr. Clackson was a postdoctoral fellow at Genentech, Inc. from 1991 to 1994 prior to his joining ARIAD in December 1994. Dr. Clackson currently serves on the Board of Directors of MassBio.